A Study of MK-6213 Co-Administered With Atorvastatin in Participants With Hypercholesterolemia (MK-6213-006)

• Status: Completed
• Trial end date: 2009-01-08
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to test the safety and effectiveness of MK-6213 as compared to MK-6213/Atorvastatin in participants 18 to 75 years) with high cholesterol.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Atorvastatin; Atorvastatin Calcium; Calcium

Criteria

Inclusion Criteria:

• 18 to 75 years of age at the time of the study with high cholesterol

• Can have diabetes mellitus but is not currently on lipid lowering therapy

• Have a stable weight for >6 weeks

Exclusion Criteria:

• Has significant cardiovascular (heart), renal (kidney), neurologic (nervous system), respiratory (lung), hepatic (liver) or metabolic disease

• history of mental instability or drug/alcohol abuse within the past 5 years

• Pregnant or nursing; human immunodeficiency virus (HIV) positive; history of cancer within the past 5 years or participation in an investigational trial within the last 30 days